Antibody Epitope Mapping — Methods, Resolution, and How to Interpret Results

What does the Fc region do?

The fragment crystallizable (Fc) region comprises the CH2 and CH3 domains of both heavy chains. It mediates three critical functions: binding to Fcγ receptors (FcγRs) on immune cells to trigger antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), activating the classical complement cascade (CDC) via C1q binding, and engaging the neonatal Fc receptor (FcRn) to enable pH-dependent recycling that extends serum half-life to ~21 days for IgG1. The N-linked glycan at Asn297 in the CH2 domain is essential for maintaining the open Fc conformation required for FcγR engagement; removing or modifying this glycan profoundly alters effector function.

How can effector functions be enhanced?

For oncology antibodies that rely on immune-mediated tumor killing, enhancing ADCC or CDC can improve clinical efficacy. Two main approaches are used:

Afucosylation is achieved through glycoengineering of the production cell line — either by knocking out the fucosyltransferase gene (FUT8) or by using engineered CHO cells with modified glycosylation pathways. This approach is purely glycan-based and does not require sequence changes to the antibody itself.

What is a silent Fc and when is it needed?

Not every therapeutic antibody benefits from effector function. Checkpoint inhibitors (anti-PD-1, anti-PD-L1), T-cell engagers, and antibodies used purely for receptor blocking need to avoid killing the cells they bind. A “silent” or “effector-null” Fc eliminates FcγR and C1q binding while retaining FcRn-mediated half-life extension. Common silent Fc mutations include:

How is half-life engineering achieved?

IgG half-life is governed by pH-dependent binding to FcRn: the antibody binds FcRn at pH 6.0 in the acidic endosome, is recycled to the cell surface, and released at pH 7.4. Mutations that increase FcRn binding affinity at pH 6.0 without increasing binding at pH 7.4 extend serum half-life. The most validated approach is the YTE mutation set (M252Y/S254T/T256E), which extends half-life approximately 4-fold in humans (from ~21 days to ~80–100 days). The LS mutation pair (M428L/N434S) achieves similar extension and has been incorporated into several clinical-stage antibodies.

Extended half-life is particularly valuable for antibodies targeting chronic diseases (autoimmune conditions, osteoporosis) where less frequent dosing improves patient compliance, and for prophylactic antibodies where sustained serum levels are essential for protection. Conversely, for imaging or radiotherapy conjugates, a shorter half-life may be desirable to reduce off-target radiation exposure — achieved by mutations that weaken FcRn binding (e.g., I253A/H310A).

Can Fc engineering be combined with other modifications?

Yes, and multi-attribute Fc engineering is increasingly standard. A typical oncology antibody might combine ADCC-enhancing mutations (or afucosylation) with half-life extension (YTE or LS). A bispecific T-cell engager might use a silent Fc (LALA-PG) with half-life extension to enable once-weekly dosing without unwanted cytokine release from FcγR crosslinking. The key constraint is that mutations in the CH2–CH3 interface can affect both FcγR binding and FcRn binding, so combinations must be validated empirically. SPR-based binding kinetics for each Fc receptor and FcRn at both pH 6.0 and 7.4 is the standard characterization approach for engineered Fc variants.

How does IgG subclass choice relate to Fc engineering?